Mirzaten Q-Tab (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten Q-Tab, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirzaten Q-Tab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive disorder with anxiety: alleviates both mood and anxiety components. - Treatment‑resistant depression: used as an adjunct when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hypersensitivity reactions including Stevens‑Johnson syndrome - Suicidal thoughts or behavior, especially early in therapy - Hepatic dysfunction - Severe hypotension

When prescribing Mirzaten Q-Tab, clinicians should consider several safety measures.

- Monitor weight: patients often experience increased appetite and weight gain. - Assess liver function: use with caution in hepatic impairment. - Evaluate for suicidal ideation: close monitoring during the initial treatment period. - Use cautiously in the elderly: heightened risk of sedation and falls. - Avoid abrupt discontinuation: taper the dose under medical supervision. - Store at ambient temperature: keep in the original container, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic antidepressants: potential serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin): may alter plasma concentrations. - Anticoagulants such as warfarin: monitor INR. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation.